(Q36859528)

16 August 2017

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study (English)

1 reference

16 August 2017

0 references

Philipp von Rosenstiel

series ordinal

10

object named as

Philipp von Rosenstiel

1 reference

16 August 2017

5

Hans-Peter Hartung

1 reference

16 August 2017

12

Ludwig Kappos

1 reference

16 August 2017

3

Frederik Barkhof

1 reference

16 August 2017

4

Giancarlo Comi

1 reference

16 August 2017

9

Shannon Ritter

1 reference

16 August 2017

2

Bhupendra Khatri

1 reference

16 August 2017

6

Xavier Montalban

1 reference

16 August 2017

8

Tracy Stites

1 reference

16 August 2017

11

Davorka Tomic

1 reference

16 August 2017

Jeffrey A Cohen

1

1 reference

16 August 2017

Jean Pelletier

series ordinal

7

1 reference

16 August 2017

TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group

series ordinal

13

1 reference

16 August 2017

language of work or name

English

0 references

publication date

25 June 2015

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

16 August 2017

1 reference

16 August 2017

87

1 reference

16 August 2017

5

1 reference

16 August 2017

468-475

1 reference

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Oral fingolimod (FTY720) for relapsing multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014) MS Journal Online: Poster Session 1

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Measures in the first year of therapy predict the response to interferon β in MS

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4853559

Regression to the mean in multiple sclerosis

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26111826

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hy's law: predicting serious hepatotoxicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26111826

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26111826

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/JNNP-2015-310597

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

26111826

1 reference